Vertex's Revenue Surges but EPS Slips
The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.
BioSpace4d
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
Zacks.com on MSN6d
Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key Metrics
The upcoming report from Vertex Pharmaceuticals (VRTX) is expected to reveal quarterly earnings of $3.99 per share, indicating a decline of 5% compared to the year-ago period. Analysts forecast ...
Yahoo Finance4d
Vertex Pharmaceuticals Incorporated (VRTX)
After hours: February 7 at 7:59:30 PM EST Loading Chart for VRTX ...
pharmaphorum3d
Vertex buys diabetes cell therapy rival ViaCyte for $320m
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
pharmaphorum1d
Vertex scores double win with non-opioid pain drug
Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.
Yahoo Finance4d
Vertex, Inc. (VERX)
After hours: February 7 at 7:31:24 PM EST Loading Chart for VERX ...